	US 12,324,811 B2
	Intranasal formulation
Geena Malhotra, Mumbai (IN); Sarabjit Singh, Thane (IN); Kalindi Gandhi, Mumbai (IN); and Vipul Mittal, Thane (IN)
Assigned to CIPLA LIMITED, Mumabi (IN)
Appl. No. 17/415,966
Filed by CIPLA LIMITED, Mumbai (IN)
PCT Filed Dec. 18, 2019, PCT No. PCT/IN2019/050932 § 371(c)(1), (2) Date Jun. 18, 2021, PCT Pub. No. WO2020/129085, PCT Pub. Date Jun. 25, 2020.
Claims priority of application No. 201821047778 (IN), filed on Dec. 18, 2018.
Prior Publication US 2021/0379080 A1, Dec. 9, 2021
Int. Cl. A61K 31/5517 (2006.01); A61K 9/00 (2006.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01)

CPC A61K 31/5517 (2013.01) [A61K 9/0043 (2013.01); A61K 47/183 (2013.01); A61K 47/186 (2013.01); A61K 47/26 (2013.01)]

13 Claims

1. A pharmaceutical formulation in the form of an aqueous solution for intranasal administration comprising midazolam at a concentration of 5% w/w of the formulation, polysorbate 80 as a surfactant at a concentration of 2.5% w/w of the formulation and pharmaceutically acceptable excipients.